Absci Raises $100M for Endometriosis, Hair Loss Therapies with Lilly Backing

Absci, a biotechnology company, announced it has raised $100 million in a funding round supported by Eli Lilly (NYSE: LLY) to advance its lead drug candidates for endometriosis and pattern hair loss. The funding coincides with the release of positive Phase I clinical data.

Details

Absci will use the funds to push its lead asset further down the clinical pipeline. The company did not disclose the exact contribution from each investor, but Eli Lilly was a key backer.

Context

Absci is a leader in AI-driven drug discovery, and its Phase I data showed promising safety and early efficacy signals. The funding comes amid growing interest in endometriosis treatments, which affect about 10% of women of reproductive age, and hair loss therapies, which impact millions of men and women.

What This Means for Investors

The funding is a significant boost for Absci and strengthens its partnership with Eli Lilly. For LLY investors, it signals potential expansion into new therapeutic areas. However, the therapies are still in early stages and require larger clinical trials before reaching the market.